Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

NCT02309450 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER_GOV

Sponsor class

Stopped BMS decision

Conditions

Hepatitis C Virus Genotype 4 Infection

Interventions

DRUG: .Asunaprevir, Daclatasvir and BMS - 791325

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]